drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Lentivirally engineered CAR T cells targeting CD123; administered IV at 2×10^6–1×10^7 CAR-T/kg with dose escalation; designed for MHC-independent cytotoxicity against CD123+ myeloid blasts.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous/allogeneic T cells are lentivirally engineered to express an anti‑CD123 chimeric antigen receptor. Upon binding CD123 on myeloid blasts, the CAR provides MHC‑independent activation signaling that drives T‑cell activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of CD123+ tumor cells.
drug_name
CD123-directed CAR T cells
nct_id_drug_ref
NCT06849921